依达拉奉联合奥扎格雷钠治疗进展性脑梗死临床观察  

Clinical observation of edaravone and ozagrel in the treatment of progressive cerebral infarction

作　　者：刘丽艳[1] 季晓宇[1] 

机构地区：[1]江苏连云港市第一人民医院东方医院,连云港222042

出　　处：《中国实用神经疾病杂志》2011年第19期16-18,共3页Chinese Journal of Practical Nervous Diseases

摘　　要：目的观察依达拉奉联合奥扎格雷钠治疗进展性脑梗死的疗效和安全性。方法符合进展性脑梗死标准的82例患者随机分为观察组42例和对照组40例。对照组患者给予常规治疗+奥扎格雷钠;观察组给予常规治疗+奥扎格雷钠+依达拉奉。2组疗程均为21d。2组患者于治疗前后进行NIHSS神经功能缺损评分、日常生活能力(ADL)评分和hs-CRP、D-二聚体的测定。结果治疗21d后,观察组痊愈率和总有效率均显著高于对照组(χ2=4.0397,4.8308,P均<0.05)。在hs-CRP、D-二聚体、NIHSS评分、ADL评分四项指标方面,治疗后观察组均显著优于对照组(t=2.4486,2.5964,2.1936,7.0401,P<0.05)。结论依达拉奉与奥扎格雷钠联合治疗进展性脑梗死有协同效果,优于奥扎格雷钠单药治疗,无明显不良反应。Objective To observe the efficacy and safety of edaravone and ozagrel in the treatment of progressive cerebral infarction. Methods Eighty-two patients that met the standards of progressive cerebral infarction were randomly divided into observation group（42 patients）and control group（40 patients）. The control group was given conventional treatment and ozagrel without edaravone; The treatment group received conventional treatment, edaravone and ozagrel. Two groups were treated for 21 days. NIHSS neurological function, activities of daily living （ADL） score and hs-CRP, D-dimer was determined before and after treatment in patients of the two groups. Results After 21 days therapy, the cure rate and total effective in the observa tion group were significantly higher than the control grouP（X2 4. 0397,4. 8308, all P^0.05）. Four indicators of the observa- tion group were significantly better than the control group after treatment in hs-CRP, D-dimer, NIHSS score, ADL score areas （t=2. 4486,2. 5964,2. 1936,7. 0401,P^0.05）. Conclusion It has a synergistic effect that Edaravone combined Ozagrel in the treatment of progressive cerebral infarction, which was better than ozagrel monotherapy, without obvious side effect.

关 键 词：进展型脑梗死 依达拉奉 奥扎格雷 超敏C反应蛋白 D-二聚体 神经功能缺损 

分 类 号：R743.33[医药卫生—神经病学与精神病学]